Children's Healthcare of Atlanta (CHOA), Egleston
Atlanta, Georgia, 30322, United States
NCT Number: NCT03932240
This primary aim of this study is to compare the in vivo effects of fibrinogen concentrate and cryoprecipitate on the neonatal fibrin network after surgery with cardiopulmonary bypass to develop effective and safe strategies for managing coagulopathies in neonates.
Looking for future studies?
Notify Me1 day–30 day
All sexes
Interventional
Phase 3
Atlanta, Georgia, 30322, United States
This study is a prospective, randomized control trial comparing two different sources of fibrinogen on clot kinetics (degradation and structure) in post-CPB coagulopathy in neonates undergoing cardiac surgery. The two sources of fibrinogen include the blood product, cryoprecipitate, and a blood product alternative, fibrinogen concentrate. Cryoprecipitate is an allogenic blood product that requires cross-matching and thawing prior to administration and is associated with immunologic reactions and possible pathogen transmission. Fibrinogen concentrate, a blood product alternative, is a purified form of fibrinogen, which undergoes a pasteurization process to minimize the risk of immunologic and allergic reactions. The primary aim of this study is compare the in vivo effect of post-CPB administration of FC, a blood product alternative, to cryoprecipitate on neonatal clot properties and clinical outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
Other names: RiaSTAP
The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
Time frame: From induction of anesthesia to 24 hours postoperatively
Blood samples were obtained from an arterial line that was required for the planned surgical procedure. Samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. Clot degradation was determined by degradation kinetic study. Blood samples were collected at four time points:1) baseline sample within 24 hours of surgery and after induction of anesthesia prior to CPB; 2) after termination of CPB and transfusion of platelets and either cryoprecipitate or fibrinogen (within 1 hour of separation from bypass; 3) upon arrival to the ICU; 4) 24 hours post-operatively. The primary outcome is to examine differences in clot degradation between study arms at 24 hours post-surgery.
Time frame: From induction of anesthesia to 24 hours postoperatively
Blood samples will be obtained from an arterial line that is required for the planned surgical procedure. They will be centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. Strength will be assessed by rheology and atomic force microscopy (AFM).
Time frame: From induction of anesthesia to 24 hours postoperatively
Blood samples will be obtained from an arterial line that is required for the planned surgical procedure. They will be centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. Polymerization will be determined by thrombin-initiated turbidity/absorbency curves.
Time frame: From induction of anesthesia to 24 hours postoperatively
Clot structure is assessed by examination of images of clot fibrin fiber alignment. Quantification of clot fiber alignment was achieved through the application of an automated algorithm based on a fast Fourier transform that measures the alignment of the fibers, as well as visual inspection. A reference range has not been established for neonates, however, higher values indicate more dense clot structure.
Time frame: During surgery (up to 6 hours)
Blood product transfusion requirements were obtained from electronic medical records. An increased transfusion requirement indicates increased interoperative bleeding, thus, lower values are preferable.
Time frame: 24 hours postoperatively
Transfusion requirements within the first 24 hours of surgery were obtained from electronic medical records.
Time frame: Up to 24 hours postoperatively
Post-operative bleeding was recorded by 24 hour chest tube output. Higher values indicate greater post-operative bleeding.
Time frame: Time of extubation (up to 2 weeks)
Mechanical ventilation time was obtained from medical records. Higher values indicate increased need for mechanical ventilation.
Time frame: At discharge from ICU (typically up to 21 days)
Length of ICU stay was obtained from medical records. A shorter ICU stay indicates a favorable state of health.
Time frame: At discharge from hospital (up to 150 days)
Length of hospital stay was obtained from medical records. A shorter hospital stay indicates a favorable state of health.
Time frame: Within seven days of surgery
Adverse events within seven days of surgery were obtained from medical records.
Time frame: Within the first 24 hours of surgery
The number of events of clinically significant postoperative thrombosis that required treatment were obtained from medical records.
Time frame: From induction of anesthesia to 24 hours postoperatively
Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. Normal fibrinogen plasma values are between 0.5 to 15 mcg/mL.
Time frame: From induction of anesthesia to 24 hours postoperatively
Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. The reference range for thrombin plasma level is 0.000313 to 0.02 mcg/mL.
Time frame: From induction of anesthesia to 24 hours postoperatively
Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. The reference range for FXIII plasma level is 0.000469 to 0.03 mcg/mL.
Time frame: From induction of anesthesia to 24 hours postoperatively
Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. Lower values may indicate an increased risk of excessive bleeding.
Emory University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05875272
Cardio-pulmonary Bypass, Extracorporeal Circulation
Amiens, France
View Trial DetailsNCT05323448
Hemostasis, Hemostatics
Bordeaux, France
View Trial DetailsNCT07529106
Extraction Socket Healing, Hemostasis
Coronel Oviedo, Caaguazú Department, Paraguay
View Trial DetailsNCT07354178
Back Injuries, Blood Loss, Surgical
Seoul, Gangnam-gu, South Korea
View Trial Details